This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
blood donors | 1356 |
blood transfusion | 1166 |
whole blood | 1091 |
red blood | 906 |
mg kg | 832 |
blood group | 827 |
blood components | 740 |
blood products | 690 |
blood donation | 681 |
intensive care | 673 |
blood cells | 642 |
red cell | 638 |
clinical signs | 586 |
bone marrow | 561 |
study design | 548 |
blood pressure | 511 |
blood bank | 506 |
summary conclusions | 494 |
case studies | 487 |
blood cell | 484 |
background case | 481 |
septic shock | 454 |
critically ill | 441 |
blood flow | 431 |
red cells | 419 |
blood samples | 408 |
transfusion medicine | 400 |
mechanical ventilation | 398 |
blood supply | 394 |
design method | 387 |
ng ml | 380 |
results finding | 375 |
blood donor | 375 |
control group | 353 |
significantly higher | 350 |
mg dl | 346 |
ml kg | 345 |
care unit | 339 |
risk factors | 336 |
platelet count | 325 |
transfusion reactions | 314 |
blood loss | 304 |
two groups | 300 |
united states | 297 |
pg ml | 297 |
blood banks | 291 |
platelet concentrates | 287 |
ill patients | 286 |
significant difference | 283 |
renal failure | 272 |
peripheral blood | 259 |
blood safety | 257 |
organ failure | 257 |
transfusion service | 253 |
cardiac output | 253 |
adverse events | 251 |
respiratory distress | 250 |
blood collection | 249 |
critical care | 248 |
nucleic acid | 247 |
statistically significant | 237 |
patients undergoing | 236 |
blood product | 235 |
blood groups | 235 |
blood donations | 233 |
liver transplantation | 231 |
flow cytometry | 229 |
mean age | 227 |
heart rate | 226 |
acute respiratory | 224 |
liver disease | 222 |
respiratory failure | 221 |
lymph nodes | 220 |
frozen plasma | 217 |
cardiac surgery | 217 |
significant differences | 214 |
nitric oxide | 214 |
side effects | 213 |
lung injury | 211 |
body weight | 211 |
blood glucose | 206 |
blood volume | 205 |
arterial blood | 200 |
may also | 198 |
blood type | 197 |
performed using | 194 |
blood units | 191 |
present study | 190 |
blood component | 189 |
fresh frozen | 189 |
blood center | 188 |
factor viii | 186 |
abo blood | 180 |
sickle cell | 180 |
clinical trials | 179 |
blood services | 177 |
bacterial contamination | 177 |
blood transfusions | 177 |
transfusion services | 176 |
pregnant women | 176 |
trauma patients | 174 |
endothelial cells | 172 |
see chapter | 170 |
within hours | 168 |
massive transfusion | 166 |
iu ml | 166 |
diabetes mellitus | 166 |
stem cell | 165 |
university hospital | 163 |
significantly lower | 163 |
may occur | 160 |
inflammatory response | 157 |
apache ii | 156 |
ml min | 155 |
kg iv | 154 |
severe hepatitis | 153 |
multiple organ | 152 |
quality control | 151 |
patients admitted | 150 |
hemolytic anemia | 150 |
clinically significant | 150 |
autologous blood | 149 |
blood gas | 148 |
coagulation factors | 147 |
mm hg | 146 |
pulmonary edema | 145 |
transfusion reaction | 145 |
room temperature | 145 |
results findings | 144 |
health care | 143 |
mortality rate | 142 |
platelet transfusion | 142 |
high risk | 142 |
heart failure | 142 |
septic patients | 142 |
national blood | 141 |
increased risk | 141 |
risk factor | 141 |
central venous | 140 |
years old | 139 |
blood centers | 139 |
statistical analysis | 139 |
icu patients | 138 |
design methods | 138 |
liver failure | 137 |
patients receiving | 137 |
rbc units | 136 |
mg ml | 135 |
platelet aggregation | 135 |
first time | 135 |
acute lung | 133 |
immune response | 133 |
retrospective study | 132 |
patients received | 132 |
red cross | 132 |
arterial pressure | 132 |
pulmonary artery | 132 |
blood system | 131 |
important role | 131 |
rbc transfusion | 131 |
donor selection | 131 |
determine whether | 129 |
significantly increased | 128 |
distress syndrome | 128 |
immune system | 128 |
infectious diseases | 128 |
may cause | 127 |
cardiac arrest | 126 |
oxygen delivery | 125 |
antibody screening | 125 |
positive results | 125 |
antiglobulin test | 124 |
pathogen inactivation | 124 |
white blood | 123 |
pulmonary hypertension | 123 |
blood service | 122 |
clinical practice | 122 |
hbv dna | 122 |
cell disease | 122 |
patients without | 120 |
adverse effects | 120 |
stem cells | 119 |
transfusion therapy | 118 |
myocardial infarction | 118 |
study period | 116 |
infectious disease | 116 |
hemorrhagic shock | 115 |
least one | 115 |
blood vessels | 115 |
plasma samples | 115 |
mechanically ventilated | 115 |
iron deficiency | 115 |
significant increase | 114 |
median age | 114 |
prospective study | 114 |
organ dysfunction | 113 |
gastrointestinal tract | 113 |
may lead | 113 |
hepatic encephalopathy | 113 |
year old | 113 |
adverse reactions | 112 |
venous blood | 112 |
donor screening | 112 |
group i | 112 |
pathogen reduction | 111 |
chain reaction | 111 |
results suggest | 111 |
plasma levels | 110 |
platelet function | 110 |
disseminated intravascular | 110 |
commercially available | 110 |
informed consent | 109 |
case report | 109 |
normal range | 108 |
positive samples | 108 |
hemolytic transfusion | 108 |
monoclonal antibodies | 107 |
renal function | 106 |
pulmonary vascular | 106 |
mean arterial | 106 |
intravascular coagulation | 106 |
nervous system | 105 |
one patient | 105 |
may result | 105 |
total number | 105 |
medical center | 104 |
logistic regression | 104 |
polymerase chain | 104 |
molecular weight | 103 |
significantly different | 103 |
coronary artery | 103 |
transfusion practice | 103 |
care units | 102 |
hcv rna | 102 |
platelet counts | 102 |
results indicate | 102 |
blood sample | 101 |
vascular resistance | 101 |
amino acid | 101 |
cd cells | 101 |
first hours | 101 |
regression analysis | 99 |
donated blood | 99 |
icu stay | 99 |
spinal cord | 99 |
metabolic acidosis | 99 |
physical examination | 99 |
public health | 98 |
significantly reduced | 97 |
safe blood | 97 |
urinary tract | 97 |
necrosis factor | 96 |
icu admission | 96 |
platelet transfusions | 95 |
heart disease | 95 |
infectious agents | 95 |
cell count | 95 |
results show | 95 |
group system | 95 |
smooth muscle | 95 |
monoclonal antibody | 94 |
data suggest | 94 |
clinical trial | 94 |
ex vivo | 94 |
class i | 93 |
patients treated | 93 |
hospital mortality | 92 |
gas exchange | 92 |
acute phase | 92 |
pediatric patients | 91 |
blood banking | 91 |
gene expression | 91 |
severe acute | 91 |
per year | 90 |
type ii | 90 |
portal vein | 90 |
transfusion safety | 89 |
histologic study | 89 |
commonly used | 88 |
hospital blood | 88 |
tumor necrosis | 87 |
cord uid | 87 |
doc id | 87 |
long term | 87 |
buffy coat | 87 |
west nile | 86 |
see also | 86 |
type i | 86 |
pao fio | 86 |
surface area | 86 |
donor blood | 86 |
donate blood | 86 |
year period | 86 |
blood cultures | 85 |
recent years | 85 |
general population | 85 |
tidal volume | 85 |
measured using | 85 |
kg min | 85 |
antibody screen | 85 |
carbon dioxide | 85 |
replacement therapy | 85 |
female donors | 84 |
emergency department | 84 |
last years | 83 |
lymph node | 83 |
cell transfusion | 83 |
virus infection | 83 |
high frequency | 83 |
united kingdom | 82 |
red pulp | 82 |
time pcr | 82 |
see table | 82 |
one case | 82 |
time donors | 82 |
respiratory tract | 82 |
kg day | 82 |
platelet activation | 82 |
two different | 82 |
direct antiglobulin | 82 |
respiratory rate | 82 |
severe sepsis | 82 |
activated charcoal | 81 |
immunodeficiency virus | 81 |
patients died | 81 |
clotting factors | 81 |
specific antibodies | 81 |
false positive | 81 |
left ventricular | 81 |
nile virus | 80 |
associated conditions | 80 |
within days | 80 |
orogastric lavage | 80 |
human immunodeficiency | 79 |
canadian blood | 79 |
coagulation factor | 79 |
voluntary blood | 78 |
possible associated | 78 |
adult patients | 78 |
healthy volunteers | 78 |
window period | 78 |
transfused patients | 78 |
specimen preparation | 78 |
intravenous fluids | 78 |
prothrombin time | 78 |
related acute | 77 |
observational study | 77 |
oxygen saturation | 77 |
acute renal | 77 |
age group | 76 |
cfu ml | 76 |
surgical patients | 76 |
blood management | 76 |
retrospective analysis | 76 |
blood plasma | 76 |
transfusion transmitted | 75 |
liver function | 75 |
group ii | 75 |
test results | 75 |
cord blood | 75 |
fresh whole | 75 |
platelet products | 75 |
plasma exchange | 75 |
urine output | 75 |
world health | 75 |
th day | 75 |
general anesthesia | 75 |
brain injury | 75 |
central nervous | 74 |
apheresis platelets | 74 |
cell surface | 74 |
significantly decreased | 74 |
flow rate | 74 |
hla antibodies | 74 |
fluid therapy | 74 |
cerebral malaria | 74 |
may require | 74 |
within minutes | 73 |
statistical significance | 73 |
antibody identification | 73 |
two patients | 73 |
respiratory syndrome | 73 |
storage time | 73 |
kg po | 73 |
human blood | 73 |
co removal | 72 |
blood gases | 72 |
reactive protein | 72 |
allogeneic blood | 72 |
cd cd | 72 |
endotracheal tube | 72 |
high dose | 72 |
standard deviation | 72 |
month period | 72 |
airway pressure | 72 |
among blood | 72 |
body temperature | 72 |
survival rate | 71 |
clinical course | 71 |
von willebrand | 71 |
one year | 71 |
epithelial cells | 71 |
acid testing | 70 |
clinical outcomes | 70 |
cohort study | 70 |
linear regression | 70 |
high levels | 70 |
per unit | 70 |
abdominal pain | 70 |
high prevalence | 70 |
negative blood | 70 |
previous studies | 70 |
adhesion molecules | 70 |
packed red | 70 |
birth weight | 70 |
pulmonary embolism | 70 |
serum albumin | 70 |
urinary bladder | 70 |
endothelial cell | 69 |
patient care | 69 |
genomic dna | 69 |
rhd gene | 69 |
ii score | 69 |
hospital stay | 69 |
see section | 69 |
results showed | 69 |
group antigens | 69 |
systemic inflammatory | 68 |
supplemental oxygen | 68 |
expected findings | 68 |
predictive value | 68 |
patient blood | 68 |
additive solution | 68 |
cardiac index | 68 |
blood count | 68 |
significant correlation | 68 |
significant reduction | 68 |
analyzed using | 68 |
may contribute | 68 |
liver cirrhosis | 68 |
amino acids | 67 |
bacterial infection | 67 |
hbv infection | 67 |
lactate levels | 67 |
transfusion recipients | 67 |
antibiotic therapy | 67 |
randomized controlled | 66 |
drug administration | 66 |
large number | 66 |
day mortality | 66 |
chronic liver | 66 |
per day | 66 |
blood screening | 66 |
plasma concentrations | 66 |
decision making | 66 |
cell lymphoma | 66 |
clinically relevant | 66 |
viral load | 65 |
related terms | 65 |
high incidence | 65 |
hiv infection | 65 |
growth factor | 65 |
regional blood | 65 |
viral infections | 65 |
clinical studies | 64 |
acute pancreatitis | 64 |
general hospital | 64 |
hospital transfusion | 64 |
transfusion transmission | 64 |
foreign body | 64 |
willebrand factor | 64 |
underlying disease | 64 |
antigen expression | 64 |
three groups | 64 |
hematopoietic stem | 64 |
patient safety | 63 |
serum samples | 63 |
medical records | 63 |
jakob disease | 63 |
positive blood | 63 |
well tolerated | 63 |
blood culture | 63 |
indirect antiglobulin | 62 |
hepatic failure | 62 |
rich plasma | 62 |
tissue factor | 62 |
per patient | 62 |
ventilated patients | 62 |
systematic review | 62 |
surgical procedures | 62 |
high mortality | 62 |
white cell | 62 |
jugular vein | 61 |
significant decrease | 61 |
renal replacement | 61 |
ferritin levels | 61 |
rhce ce | 61 |
quality assurance | 61 |
buffy coats | 61 |
venous pressure | 61 |
patients suffering | 61 |
three days | 61 |
male donors | 61 |
may help | 60 |
plasma units | 60 |
wide range | 60 |
healthy donors | 60 |
widely used | 60 |
source plasma | 60 |
previously reported | 60 |
right ventricular | 60 |
bact alert | 60 |
abo rh | 60 |
bacterial growth | 60 |
clinical outcome | 60 |
animal models | 60 |
health organization | 60 |
isothermal amplification | 60 |
three patients | 59 |
clinical manifestations | 59 |
results obtained | 59 |
human plasma | 59 |
blood coagulation | 59 |
growth factors | 59 |
transmitted infections | 59 |
donor population | 59 |
soft tissue | 59 |
monoclonal anti | 59 |
controlled trial | 59 |
external examination | 58 |
submit samples | 58 |
increased mortality | 58 |
hepatorenal syndrome | 58 |
fatty acids | 58 |
body mass | 58 |
low molecular | 58 |
rbc transfusions | 58 |
class ii | 57 |
chagas disease | 57 |
portal hypertension | 57 |
consecutive patients | 57 |
pilot study | 57 |
quality management | 57 |
severe cases | 57 |
cell lines | 57 |
two years | 57 |
platelets stored | 57 |
serum levels | 57 |
included patients | 57 |
hemolytic disease | 57 |
repeat donors | 57 |
among patients | 57 |
clot formation | 57 |
sofa score | 57 |
oxidative stress | 56 |
significant changes | 56 |
renal disease | 56 |
even though | 56 |
patient population | 56 |
patients may | 56 |
higher risk | 56 |
postoperative period | 56 |
screening test | 56 |
high level | 56 |
cell concentrates | 56 |
healthy individuals | 56 |
post transfusion | 56 |
laboratory tests | 56 |
small number | 56 |
also occur | 56 |
rare blood | 56 |
donor deferral | 56 |
column agglutination | 56 |
healthy dogs | 56 |
hb level | 56 |
clinical use | 56 |
blood centre | 56 |
plasminogen activator | 55 |
increased significantly | 55 |
screening tests | 55 |
three different | 55 |
well known | 55 |
veterinary medicine | 55 |
allergic reactions | 55 |
parenteral nutrition | 55 |
skeletal muscle | 55 |
clotting time | 55 |
clinical significance | 55 |
positive result | 55 |
one hour | 55 |
many cases | 55 |
inflammatory cytokines | 55 |
pleural effusion | 55 |
blood types | 55 |
naturally occurring | 55 |
study group | 55 |
reference laboratory | 55 |
time points | 55 |
acute kidney | 54 |
vein thrombosis | 54 |
saline solution | 54 |
therapeutic plasma | 54 |
intravenous fluid | 54 |
critical illness | 54 |
patients showed | 54 |
host disease | 54 |
scansystem tm | 54 |
congestive heart | 54 |
every hours | 54 |
foreign bodies | 53 |
five patients | 53 |
clinical symptoms | 53 |
bacterial culture | 53 |
nucleic acids | 53 |
days post | 53 |
abstract withdrawn | 53 |
low levels | 53 |
positive dat | 53 |
cell antigens | 53 |
tissue oxygenation | 53 |
cardiogenic shock | 53 |
also may | 53 |
alcohol consumption | 53 |
kg body | 53 |
sample size | 53 |
routine use | 53 |
electron microscopy | 53 |
study included | 52 |
whenever possible | 52 |
first step | 52 |
blood establishments | 52 |
oxygen consumption | 52 |
three times | 52 |
novel coronavirus | 52 |
complete blood | 52 |
two cases | 52 |
pressure support | 52 |
fetal dna | 52 |
poor prognosis | 52 |
apheresis platelet | 52 |
cancer patients | 52 |
serum creatinine | 52 |
storage period | 52 |
preliminary results | 52 |
cardiopulmonary bypass | 52 |
transfusion requirements | 52 |
gas analysis | 52 |
tract infection | 52 |
response syndrome | 51 |
burn injury | 51 |
blood collected | 51 |
hla class | 51 |
respiratory system | 51 |
inflammatory mediators | 51 |
acute myocardial | 51 |
cell units | 51 |
units per | 51 |
trima accel | 51 |
clinical data | 51 |
study showed | 51 |
multiple myeloma | 51 |
arachidonic acid | 51 |
kidney injury | 51 |
iron stores | 51 |
bacterial infections | 51 |
shelf life | 51 |
information system | 51 |
mononuclear cells | 51 |
treated rbcs | 51 |
component therapy | 51 |
fluid resuscitation | 50 |
fully automated | 50 |
tissue damage | 50 |
hemoglobin levels | 50 |
may develop | 50 |
cell transplantation | 50 |
plt count | 50 |
donor samples | 50 |
weight loss | 50 |
single donor | 50 |
platelet units | 50 |
age years | 50 |
also found | 50 |
major surgery | 50 |
significantly associated | 50 |
tertiary care | 50 |
common cause | 50 |
platelet concentrate | 50 |
mean value | 50 |
septal defect | 50 |
cell types | 50 |
residual risk | 50 |
treated patients | 49 |
marrow transplantation | 49 |
hand column | 49 |
factor vii | 49 |
may play | 49 |
high doses | 49 |
small animal | 49 |
endemic areas | 49 |
hematopoietic cells | 49 |
plasma donation | 49 |
patients requiring | 49 |
type diabetes | 49 |
gel test | 49 |
blood grouping | 49 |
bacterial translocation | 49 |
wound healing | 49 |
premature infants | 49 |
transplant recipients | 49 |
i ii | 49 |
western blot | 48 |
marginal zone | 48 |
low hb | 48 |
hospitalized patients | 48 |
vena cava | 48 |
american red | 48 |
induce emesis | 48 |
oral administration | 48 |
transfusion practices | 48 |
treated cells | 48 |
emerging infectious | 48 |
inventory management | 48 |
age groups | 48 |
negative results | 48 |
total body | 48 |
management system | 48 |
escherichia coli | 48 |
metabolic alkalosis | 48 |
serious adverse | 48 |
platelet storage | 47 |
immune responses | 47 |
mucous membranes | 47 |
acute liver | 47 |
coronavirus disease | 47 |
mediated isothermal | 47 |
normal saline | 47 |
surgery patients | 47 |
plasma products | 47 |
two days | 47 |
rhd negative | 47 |
platelet antigens | 47 |
analysis showed | 47 |
packed rbcs | 47 |
total protein | 47 |
mortality rates | 47 |
pulse oximetry | 46 |
center background | 46 |
reperfusion injury | 46 |
cardiac failure | 46 |
thrombin generation | 46 |
years ago | 46 |
positive donations | 46 |
sample collection | 46 |
study shows | 46 |
teaching hospital | 46 |
lupus erythematosus | 46 |
kg hour | 46 |
tested using | 46 |
iron supplementation | 46 |
positive donors | 46 |
family members | 46 |
significant antibodies | 46 |
rhd genotyping | 46 |
adverse reaction | 46 |
severe thrombocytopenia | 46 |
large numbers | 46 |
time blood | 46 |
infected patients | 45 |
alloimmune thrombocytopenia | 45 |
healthy controls | 45 |
evaluated using | 45 |
rheumatoid arthritis | 45 |
flow cytometric | 45 |
gastrointestinal bleeding | 45 |
thromboplastin time | 45 |
platelet components | 45 |
currently available | 45 |
will help | 45 |
high sensitivity | 45 |
systemic vascular | 45 |
respiratory disease | 45 |
data indicate | 45 |
platelet pools | 45 |
mean values | 45 |
heart surgery | 45 |
pediatric intensive | 45 |
cytokine production | 45 |
one study | 45 |
decreased significantly | 45 |
three months | 45 |
transfusion protocol | 45 |
ejection fraction | 45 |
assessed using | 45 |
past years | 45 |
pr plts | 45 |
blood smear | 45 |
venous thrombosis | 45 |
gene therapy | 45 |
iron overload | 44 |
primary outcome | 44 |
care medicine | 44 |
perform orogastric | 44 |
one month | 44 |
emergency care | 44 |
iron depletion | 44 |
degradation products | 44 |
hcv infection | 44 |
serum ferritin | 44 |
one week | 44 |
rh blood | 44 |
detection limit | 44 |
one unit | 44 |
may provide | 44 |
submit sample | 44 |
transfusion related | 44 |
cardiovascular disease | 44 |
positive antibody | 44 |
apc resistance | 44 |
terumo bct | 44 |
donor recruitment | 44 |
pulmonary disease | 44 |
procedures depend | 44 |
lung disease | 44 |
study aimed | 44 |
plasma transfusion | 44 |
carbon monoxide | 43 |
tested positive | 43 |
common causes | 43 |
compatible blood | 43 |
differ significantly | 43 |
fungal infections | 43 |
reference range | 43 |
antibody tests | 43 |
sterile saline | 43 |
data collection | 43 |
different blood | 43 |
body surface | 43 |
postoperative day | 43 |
small amount | 43 |
complement activation | 43 |
probably due | 43 |
administer intravenous | 43 |
healthy subjects | 43 |
gold standard | 43 |
gram negative | 43 |
time period | 43 |
cell volume | 43 |
reference ranges | 43 |
patient samples | 43 |
upper respiratory | 43 |
early diagnosis | 43 |
cd expression | 43 |
different types | 43 |
bile duct | 43 |
potential risk | 43 |
confidence interval | 43 |
bleeding time | 43 |
chronic disease | 43 |
studied patients | 42 |
first days | 42 |
ct scan | 42 |
fold increase | 42 |
new blood | 42 |
negative bacteria | 42 |
median time | 42 |
low dose | 42 |
gestational age | 42 |
risk assessment | 42 |
medical record | 42 |
red wine | 42 |
plasma concentration | 42 |
oxygen carriers | 42 |
hb levels | 42 |
plasma cells | 42 |
cd cell | 42 |
partial thromboplastin | 42 |
real time | 42 |
well established | 42 |
platelet yield | 42 |
vital signs | 42 |
overall mortality | 42 |
will also | 42 |
coagulation system | 42 |
pet rabbits | 42 |
old female | 42 |
neonatal alloimmune | 42 |
kupffer cells | 42 |
previously described | 41 |
european countries | 41 |
intravenous catheter | 41 |
hemoglobin concentration | 41 |
lymphatic vessels | 41 |
days later | 41 |
samples collected | 41 |
grossly identified | 41 |
gamma globulin | 41 |
effective treatment | 41 |
survival time | 41 |
intravenous immunoglobulin | 41 |
animal model | 41 |
two hours | 41 |
four patients | 41 |
hbc positive | 41 |
also known | 41 |
platelet quality | 41 |
renal dysfunction | 41 |
transfusion associated | 41 |
systolic blood | 41 |
small intestine | 41 |
coagulation tests | 41 |
neonatal isoerythrolysis | 41 |
clinical samples | 40 |
air embolism | 40 |
crystalloid fluids | 40 |
transfusion center | 40 |
spontaneous breathing | 40 |
identified abnormalities | 40 |
gauge needle | 40 |
clinical features | 40 |
regular blood | 40 |
six months | 40 |
compared using | 40 |
thrombocytopenic purpura | 40 |
quality system | 40 |
cell membrane | 40 |
variant creutzfeldt | 40 |
data analysis | 40 |
inclusion criteria | 40 |
airway obstruction | 40 |
short term | 40 |
fio ratio | 40 |
data collected | 40 |
high blood | 40 |
intravascular hemolysis | 40 |
haemolytic disease | 40 |
kg bw | 40 |
may include | 40 |
single nucleotide | 40 |
adverse event | 40 |
contrast material | 40 |
prospective observational | 40 |
group systems | 40 |
positive control | 40 |
three years | 40 |
domestic animals | 40 |
medical staff | 40 |
donating blood | 40 |
patient received | 40 |
viral inactivation | 40 |
medical care | 40 |
clinical setting | 39 |
total blood | 39 |
staphylococcus aureus | 39 |
related complications | 39 |
tranexamic acid | 39 |
highly sensitive | 39 |
two types | 39 |
large amounts | 39 |
medical history | 39 |
old male | 39 |
high concentrations | 39 |
medical treatment | 39 |
patient outcomes | 39 |
two methods | 39 |
anti hpa | 39 |
head injury | 39 |
thalassaemia major | 39 |
arterial oxygen | 39 |
bleeding patients | 39 |
results demonstrate | 39 |
systemic circulation | 39 |
alkaline phosphatase | 39 |
five years | 39 |
urinary catheter | 39 |
one must | 39 |
antibody testing | 39 |
platelet concentration | 39 |
may indicate | 39 |
small amounts | 39 |
thrombus formation | 39 |
major role | 39 |
ionized calcium | 39 |
cause severe | 39 |
cobe spectra | 39 |
trypanosoma cruzi | 39 |
spectrum antibiotics | 39 |
acid amplification | 39 |
acute hemolytic | 39 |
controlled study | 38 |
ventilatory support | 38 |
vascular spaces | 38 |
left hand | 38 |
continuous infusion | 38 |
body fluids | 38 |
reported cases | 38 |
female patients | 38 |
kidney disease | 38 |
systemic lupus | 38 |
hospital discharge | 38 |
hours later | 38 |
mast cell | 38 |
blood typing | 38 |
cell proliferation | 38 |
saps ii | 38 |
relatively high | 38 |
cerebrospinal fluid | 38 |
disease process | 38 |
two weeks | 38 |
data show | 38 |
cirrhotic patients | 38 |
eligibility criteria | 38 |
affected dogs | 38 |
laboratory testing | 38 |
mast cells | 38 |
dengue virus | 38 |
mean sd | 38 |
times higher | 38 |
time course | 38 |
factors associated | 38 |
immune cells | 38 |
cell activation | 38 |
single unit | 38 |
mediated hemolytic | 38 |
solid phase | 38 |
hemoglobin level | 38 |
wine consumption | 38 |
affected foals | 38 |
cell transfusions | 38 |
menstrual fluid | 38 |
antibody detection | 38 |
showed significant | 37 |
cardiac disease | 37 |
glucose levels | 37 |
lg ml | 37 |
vascular access | 37 |
determined using | 37 |
cross blood | 37 |
recent studies | 37 |
rhodococcus equi | 37 |
control samples | 37 |
donor base | 37 |
sialic acid | 37 |
venous catheter | 37 |
average age | 37 |
receptor antagonist | 37 |
tissue perfusion | 37 |
hypovolemic shock | 37 |
disease severity | 37 |
bacterial screening | 37 |
scoring system | 37 |
blood bunch | 37 |
lymphoid tissue | 37 |
units transfused | 37 |
hypertonic saline | 37 |
may reduce | 37 |
low risk | 37 |
supply chain | 37 |
laboratory findings | 37 |
early stage | 37 |
pulp vascular | 37 |
mixed venous | 37 |
high titer | 37 |
thermal injury | 37 |
carotid artery | 37 |
many patients | 37 |
time point | 37 |
significantly correlated | 37 |
damage control | 37 |
supportive care | 37 |
molecular methods | 37 |
cell separator | 37 |
underlying cause | 37 |
serological testing | 37 |
coagulation parameters | 37 |
generation sequencing | 37 |
apheresis procedures | 37 |
kg minute | 37 |
orthotopic liver | 37 |
surgical intervention | 37 |
enzyme treated | 37 |
fl ow | 37 |
high quality | 37 |
findings suggest | 37 |
autoimmune hemolytic | 37 |
scd patients | 37 |
blood may | 37 |
stimulating factor | 36 |
animal studies | 36 |
routine blood | 36 |
beneficial effect | 36 |
square test | 36 |
differential diagnosis | 36 |
platelet adhesion | 36 |
serum potassium | 36 |
endotracheal intubation | 36 |
peritoneal cavity | 36 |
platelet kit | 36 |
developing countries | 36 |
circulatory overload | 36 |
selection criteria | 36 |
zika virus | 36 |
bleeding complications | 36 |
serious complications | 36 |
blood smears | 36 |
severe anemia | 36 |
muscle cells | 36 |
dna samples | 36 |
lateral recumbency | 36 |
tm platelet | 36 |
renal tubular | 36 |
thrombin time | 36 |
factor xiii | 36 |
hours post | 36 |
patient groups | 36 |
elderly patients | 36 |
information security | 36 |
large volume | 36 |
hospital admission | 36 |
haemolytic anaemia | 36 |
molecular biology | 36 |
cell counts | 36 |
chronic renal | 36 |
mean platelet | 36 |
clinical relevance | 36 |
enveloped viruses | 36 |
also observed | 36 |
new york | 36 |
multivariate analysis | 36 |
poor outcome | 36 |
antithrombin iii | 36 |
intravenous administration | 35 |
right ventricle | 35 |
life threatening | 35 |
table shows | 35 |
cells may | 35 |
treatment consists | 35 |
control groups | 35 |
based oxygen | 35 |
multiple trauma | 35 |
odds ratio | 35 |
abdominal cavity | 35 |
investigate whether | 35 |
oral cavity | 35 |
cardiac function | 35 |
stroke volume | 35 |
cerebral edema | 35 |
blood meals | 35 |
low blood | 35 |
group antigen | 35 |
bacterial detection | 35 |
high throughput | 35 |
left atrial | 35 |
protective effect | 35 |
liver diseases | 35 |
connective tissue | 35 |
samples tested | 35 |
plasma volume | 35 |
plasma fractionation | 35 |
early detection | 35 |
observation period | 35 |
severe liver | 35 |
massive blood | 35 |
major cause | 35 |
rhd positive | 35 |
activated protein | 35 |
sepsis syndrome | 35 |
circulating blood | 35 |
confirmed positive | 35 |
surface antigen | 35 |
common clinical | 35 |
tube method | 35 |
healthy blood | 35 |
infected blood | 35 |
human platelet | 35 |
internal medicine | 35 |
atrial fibrillation | 35 |
pcr amplification | 35 |
plasmodium falciparum | 34 |
serum concentrations | 34 |
severe ards | 34 |
intravenous crystalloid | 34 |
viral infection | 34 |
retrospective review | 34 |
thrombotic thrombocytopenic | 34 |
urine samples | 34 |
income countries | 34 |
serologic tests | 34 |
control study | 34 |
reactive oxygen | 34 |
control dogs | 34 |
lymphatic system | 34 |
systemic inflammation | 34 |
kg hr | 34 |
routinely used | 34 |
increased blood | 34 |
vitro quality | 34 |
mean hb | 34 |
significantly improved | 34 |
proinflammatory cytokines | 34 |
new donors | 34 |
positive cells | 34 |
partial pressure | 34 |
hemodynamic parameters | 34 |
membrane oxygenation | 34 |
molecular testing | 34 |
hiv positive | 34 |
eid agents | 34 |
blood alcohol | 34 |
antibody titers | 34 |
potential donors | 34 |
clinical conditions | 34 |
studies suggest | 34 |
extremely rare | 34 |
elevated levels | 34 |
several days | 34 |
transfusion guidelines | 34 |
significantly elevated | 34 |
exchange transfusion | 34 |
recent study | 34 |
sanger sequencing | 34 |
beneficial effects | 34 |
basal insulin | 34 |
nutritional support | 34 |
fecal samples | 34 |
using two | 34 |
lung cancer | 34 |
ml syringe | 34 |
transfusion policy | 33 |
soluble fibrin | 33 |
corrective actions | 33 |
normal values | 33 |
human albumin | 33 |
deep vein | 33 |
gastrointestinal disease | 33 |
liver injury | 33 |
significant improvement | 33 |
negative pressure | 33 |
higher mortality | 33 |
intercept blood | 33 |
uric acid | 33 |
platelet refractoriness | 33 |
higher incidence | 33 |
blood bags | 33 |
derived products | 33 |
procedures described | 33 |
analysis revealed | 33 |
affected animals | 33 |
artery disease | 33 |
umbilical cord | 33 |
mean duration | 33 |
carrying capacity | 33 |
jugular bulb | 33 |
copies ml | 33 |
standard operating | 33 |
normal rhd | 33 |
breast cancer | 33 |
ug ml | 33 |
reagent lots | 33 |
study will | 33 |
operating room | 33 |
last two | 33 |
make sure | 33 |
compatibility testing | 33 |
ml per | 33 |
will provide | 33 |
useful tool | 33 |
exclusion criteria | 33 |
myocardial ischemia | 33 |
also performed | 33 |
congenital heart | 33 |
ards patients | 33 |
organ damage | 33 |
normal dogs | 33 |
shock patients | 33 |
abdominal surgery | 33 |
passive transfer | 33 |
toxic effects | 33 |
controlled trials | 33 |
considered significant | 33 |
eight patients | 33 |
quality improvement | 33 |
blood levels | 33 |
aspiration pneumonia | 33 |
clinical presentation | 33 |
group received | 33 |
stored blood | 33 |
analysis using | 33 |
risk reduction | 33 |
saharan africa | 33 |
may affect | 32 |
samples obtained | 32 |
antimicrobial therapy | 32 |
within normal | 32 |
retrospective cohort | 32 |
umbilical vein | 32 |
head trauma | 32 |
response rate | 32 |
severe disease | 32 |
nat screening | 32 |
patients underwent | 32 |
blood circulation | 32 |
local anesthetic | 32 |
right atrium | 32 |
diaphragmatic hernia | 32 |
extracorporeal membrane | 32 |
hypertensive patients | 32 |
adhesion molecule | 32 |
convalescent plasma | 32 |
blood sampling | 32 |
repeated measures | 32 |
induced platelet | 32 |
free radical | 32 |
higher levels | 32 |
take place | 32 |
body condition | 32 |
viral hepatitis | 32 |
operating procedures | 32 |
low level | 32 |
rbc antigens | 32 |
platelet rich | 32 |
also cause | 32 |
possible causes | 32 |
electrolyte abnormalities | 32 |
constant rate | 32 |
severe respiratory | 32 |
recombinant factor | 32 |
statistical difference | 32 |
first day | 32 |
hpa antibodies | 32 |
severe trauma | 32 |
signal transduction | 32 |
bleeding disorders | 32 |
artery bypass | 32 |
donor center | 32 |
function tests | 32 |
gram stain | 32 |
clotting factor | 32 |
flow rates | 32 |
preliminary data | 32 |
inhibitory effect | 32 |
inventory level | 32 |
intestinal tract | 32 |
automated blood | 31 |
neonatal foals | 31 |
serum iron | 31 |
care patients | 31 |
controlled clinical | 31 |
tissue injury | 31 |
study population | 31 |
adult respiratory | 31 |
several studies | 31 |
serum sodium | 31 |
renal perfusion | 31 |
national health | 31 |
diagnostic criteria | 31 |
ethnic groups | 31 |
bronchoalveolar lavage | 31 |
blood derived | 31 |
emergency room | 31 |
dependent manner | 31 |
lactate dehydrogenase | 31 |
many countries | 31 |
done using | 31 |
life support | 31 |
lymphocyte count | 31 |
irradiated blood | 31 |
abo typing | 31 |
growth hormone | 31 |
analysed using | 31 |
cytologic examination | 31 |
data obtained | 31 |
deferred donors | 31 |
donor plasma | 31 |
ethylene glycol | 31 |
oxygen extraction | 31 |
liver transplant | 31 |
diabetic patients | 31 |
higher prevalence | 31 |
host defense | 31 |
per month | 31 |
plasma protein | 31 |
infectious complications | 31 |
femoral artery | 31 |
less frequent | 31 |
ill children | 31 |
screening assays | 31 |
incubation period | 31 |
lactic acid | 31 |
human serum | 31 |
laboratory data | 31 |
first three | 31 |
chest pain | 31 |
much lower | 31 |
transfusion process | 31 |
placebo group | 31 |
factor ix | 31 |
repeat blood | 31 |
tnf production | 31 |
following parameters | 31 |
severity score | 31 |
donor platelets | 31 |
cell line | 31 |
wbc count | 31 |
severe head | 30 |
mitral valve | 30 |
agglutination technology | 30 |
volume reduction | 30 |
next generation | 30 |
patient identification | 30 |
volume overload | 30 |
calculated using | 30 |
bowel disease | 30 |
using flow | 30 |
oxygen radicals | 30 |
enteral feeding | 30 |
homologous blood | 30 |
storage lesion | 30 |
enteral nutrition | 30 |
lipid peroxidation | 30 |
may explain | 30 |
fatty acid | 30 |
excessive bleeding | 30 |
immunosorbent assay | 30 |
transfusion chain | 30 |
pretransfusion testing | 30 |
tract infections | 30 |
patients required | 30 |
methylene blue | 30 |
method using | 30 |
iron metabolism | 30 |
received blood | 30 |
extracellular matrix | 30 |
czech republic | 30 |
blood lactate | 30 |
future studies | 30 |
increased levels | 30 |
also used | 30 |
pregnant woman | 30 |
may improve | 30 |
group ab | 30 |
fibrin monomer | 30 |
traumatic brain | 30 |
dental disease | 30 |
neoplastic cells | 30 |
improved survival | 30 |
platelet surface | 30 |
htlv i | 30 |
chronic hepatitis | 30 |
reagent red | 30 |
two samples | 30 |
young people | 30 |
final concentration | 30 |
severe anaemia | 30 |
positive correlation | 30 |
factor viia | 30 |
artery pressure | 30 |
infected donors | 30 |
transfusion protocols | 30 |
canine distemper | 30 |
protein synthesis | 30 |
oxygen therapy | 30 |
igm antibodies | 30 |
ethics committee | 30 |
pseudomonas aeruginosa | 30 |
randomized trial | 30 |
transfusion strategy | 30 |
clinical status | 30 |
thrombotic complications | 30 |
enzyme immunoassay | 30 |
white cells | 30 |
less common | 30 |
transit time | 30 |
blood ph | 30 |
south africa | 30 |
electronic medical | 30 |
nursing staff | 30 |
delayed hemolytic | 30 |
fibrinogen concentrate | 29 |
days prior | 29 |
increased susceptibility | 29 |
component preparation | 29 |
liquid chromatography | 29 |
ordering strategy | 29 |
venous thromboembolism | 29 |
positive effect | 29 |
also tested | 29 |
seven days | 29 |
may become | 29 |
medical management | 29 |
weight heparin | 29 |
remained unchanged | 29 |
cardiac injury | 29 |
one hundred | 29 |
health system | 29 |
case reports | 29 |
organ system | 29 |
cold storage | 29 |
nonsteroidal antiinflammatory | 29 |
also significantly | 29 |
months later | 29 |
toxicologic study | 29 |
false negative | 29 |
investigated whether | 29 |
lower respiratory | 29 |
blood vessel | 29 |
cell antibodies | 29 |
gamma irradiation | 29 |
inspiratory pressure | 29 |
lateral flow | 29 |
aplastic anemia | 29 |
liver enzymes | 29 |
randomly assigned | 29 |
one may | 29 |
low frequency | 29 |
viral loads | 29 |
regular donors | 29 |
rare donor | 29 |
transfusion vol | 29 |
fi rst | 29 |
thoracic radiographs | 29 |
injury severity | 29 |
transfusion committee | 29 |
protein concentration | 29 |
fluid administration | 29 |
plasma proteins | 29 |
folic acid | 29 |
fungal infection | 29 |
vascular smooth | 29 |
hour period | 29 |
treatment group | 29 |
exact test | 29 |
speci fi | 29 |
inflammatory process | 29 |
anticoagulant therapy | 29 |
intestinal mucosa | 29 |
four different | 29 |
shear stress | 29 |
hepatic artery | 29 |
progenitor cells | 29 |
baseline values | 29 |
cell separators | 29 |
least two | 29 |
standard methods | 29 |
recombinant human | 28 |
neutrophil count | 28 |
clinical characteristics | 28 |
leading cause | 28 |
data demonstrate | 28 |
potassium levels | 28 |
may present | 28 |
making process | 28 |
information regarding | 28 |
may increase | 28 |
current study | 28 |
cell death | 28 |
needle aspiration | 28 |
skin lesions | 28 |
steady state | 28 |
north america | 28 |
correlation coefficient | 28 |
renal insufficiency | 28 |
olfactory bulb | 28 |
brain death | 28 |
septic complications | 28 |
injured patients | 28 |
normal blood | 28 |
treatment groups | 28 |
four hours | 28 |
icu mortality | 28 |
human beings | 28 |
rhd typing | 28 |
ml vs | 28 |
computed tomography | 28 |
several years | 28 |
serologic testing | 28 |
neonatal intensive | 28 |
randomized trials | 28 |
confidence intervals | 28 |
postoperative complications | 28 |
cell therapy | 28 |
methods used | 28 |
rate infusion | 28 |
donor testing | 28 |
manual tube | 28 |
per rbc | 28 |
ab blood | 28 |
one sample | 28 |
babesia microti | 28 |
post irradiation | 28 |
brain barrier | 28 |
clinical evaluation | 28 |
may need | 28 |
fibrinogen levels | 28 |
way anova | 28 |
inflammatory bowel | 28 |
ventricular septal | 28 |
acute chest | 28 |
may appear | 28 |
per minute | 28 |
six patients | 28 |
oxidative damage | 28 |
cerebral blood | 28 |
pulmonary arterial | 28 |
therapeutic intervention | 28 |
nosocomial infection | 28 |
icu discharge | 28 |
first two | 28 |
disease control | 28 |
blood urea | 28 |
two units | 28 |
virus type | 28 |
mean time | 28 |
gastric ulcers | 28 |
fresh blood | 28 |
often used | 28 |
intravenous infusion | 28 |
thawed plasma | 28 |
sodium bicarbonate | 27 |
diagnostic procedures | 27 |
study aims | 27 |
white pulp | 27 |
bleeding channel | 27 |
copd patients | 27 |
first week | 27 |
serum lactate | 27 |
platelet additive | 27 |
catheter insertion | 27 |
risk patients | 27 |
oxygen species | 27 |
routine testing | 27 |
data management | 27 |
positive rate | 27 |
packed cell | 27 |
cytokine release | 27 |
demographic data | 27 |
fi cation | 27 |
magnetic resonance | 27 |
mean ae | 27 |
mediated thrombocytopenia | 27 |
specific primers | 27 |
kidney transplantation | 27 |
artery catheter | 27 |
thalassaemia patients | 27 |
tested negative | 27 |
clinical experience | 27 |
undergoing cardiac | 27 |
inflammatory reaction | 27 |
time consuming | 27 |
myeloid leukemia | 27 |
neutrophil activation | 27 |
consecutive days | 27 |
factor concentrates | 27 |
respiratory mechanics | 27 |
blood mononuclear | 27 |
upper airway | 27 |
plasma derivates | 27 |
capillary blood | 27 |
blood establishment | 27 |
patient may | 27 |
dose dependent | 27 |
voluntary donors | 27 |
health status | 27 |
barr virus | 27 |
prognostic factors | 27 |
healthy control | 27 |
early stages | 27 |
rhd exons | 27 |
continuous monitoring | 27 |
blood bag | 27 |
weeks gestation | 27 |
antibody test | 27 |
converting enzyme | 27 |
ventricular tachycardia | 27 |
hepatic dysfunction | 27 |
cardiac diseases | 27 |
central role | 27 |
will require | 27 |
clinical settings | 27 |
russian federation | 27 |
rh phenotype | 27 |
hepatopulmonary syndrome | 27 |
diagnostic tool | 27 |
activated partial | 27 |
invasive procedures | 27 |
receive blood | 27 |
lymphoid tissues | 27 |
following transfusion | 27 |
infection cases | 27 |
adverse transfusion | 27 |
pulmonary function | 27 |
catheter placement | 27 |
mesenteric lymph | 27 |
upper gastrointestinal | 27 |
reduction technology | 27 |
first study | 26 |
clinically important | 26 |
human umbilical | 26 |
extracorporeal circulation | 26 |
readily available | 26 |
lung tissue | 26 |
cardiac dysrhythmias | 26 |
bypass surgery | 26 |
individual patient | 26 |
cd deficiency | 26 |
negative result | 26 |
mean number | 26 |
vitro studies | 26 |
small intestinal | 26 |
innate immune | 26 |
days following | 26 |
clinical evidence | 26 |
nasal cavity | 26 |
nat testing | 26 |
lyme disease | 26 |
transmissible infections | 26 |
disease transmission | 26 |
much higher | 26 |
signifi cant | 26 |
finger ridge | 26 |
free radicals | 26 |
glomerular filtration | 26 |
prognostic value | 26 |
iron absorption | 26 |
extremely low | 26 |
group iii | 26 |
transfusion may | 26 |
iu kg | 26 |
restrictive transfusion | 26 |
bile ducts | 26 |
regional lymph | 26 |
general practitioners | 26 |
liver dysfunction | 26 |
marginal sinus | 26 |
treponema pallidum | 26 |
spectra optia | 26 |
safety measures | 26 |
molecules per | 26 |
cell salvage | 26 |
sample preparation | 26 |
different levels | 26 |
pooled plasma | 26 |
studies showed | 26 |
new technology | 26 |
mass spectrometry | 26 |
vasovagal reactions | 26 |
oxygen supply | 26 |
significant risk | 26 |
patients developed | 26 |
abdominal ultrasound | 26 |
mainly due | 26 |
body fluid | 26 |
human parvovirus | 26 |
improve patient | 26 |
flow velocity | 26 |
within min | 26 |
pooled platelet | 26 |
higher frequency | 26 |
leukocyte reduction | 26 |
working group | 26 |
cell function | 26 |
short period | 26 |
infusion rate | 26 |
levels may | 26 |
open heart | 26 |
fibrin glue | 26 |
following trauma | 26 |
acute myeloid | 26 |
negative correlation | 26 |
complement system | 26 |
similar results | 26 |
organ function | 26 |
hcv antibodies | 26 |
adverse outcomes | 26 |
different methods | 26 |
intravascular volume | 26 |
comparative study | 26 |
clinical efficacy | 26 |
phase ii | 26 |
quality assessment | 26 |
cell free | 26 |
filtration rate | 26 |
negative control | 26 |
may serve | 26 |
caucasian population | 26 |
allogenic blood | 26 |
study demonstrated | 26 |
broad spectrum | 26 |
therapy may | 26 |
derived platelets | 26 |
using different | 26 |
rbc unit | 26 |
nine patients | 26 |
serum calcium | 26 |
occur within | 26 |
young children | 26 |
diagnostic tests | 26 |
transfusion testing | 26 |
analytical sensitivity | 26 |
seroconversion panels | 26 |
clinical situations | 26 |
central blood | 26 |
chest wall | 26 |
coronary arteries | 26 |
may produce | 26 |
cell carcinoma | 26 |
induced thrombocytopenia | 26 |
replacement donors | 26 |
cell mass | 26 |
glasgow coma | 26 |
seven patients | 26 |
image processing | 25 |
significantly greater | 25 |
coagulation activation | 25 |
fingerprint patterns | 25 |
relatively low | 25 |
heparin therapy | 25 |
cost effective | 25 |
fluid overload | 25 |
compatible platelets | 25 |
iv cri | 25 |
ten patients | 25 |
hemodynamic changes | 25 |
selectin expression | 25 |
negative sepsis | 25 |
least days | 25 |
immune function | 25 |
endemic area | 25 |
necrotizing enterocolitis | 25 |
donor cells | 25 |
significant association | 25 |
likely due | 25 |
oxygen content | 25 |
automated system | 25 |
fatal outcome | 25 |
volume expansion | 25 |
capillary permeability | 25 |
blood parameters | 25 |
many years | 25 |
surgical procedure | 25 |
thrombocytopenic patients | 25 |
intravenous injection | 25 |
receiver operating | 25 |
major abdominal | 25 |
independently associated | 25 |
deferral rates | 25 |
positive predictive | 25 |
gel cards | 25 |
platelet content | 25 |
also determined | 25 |
collected data | 25 |
may vary | 25 |
thrombolytic therapy | 25 |
demand forecasting | 25 |
positive direct | 25 |
positive patients | 25 |
stored platelets | 25 |
stage liver | 25 |
university school | 25 |
hepatitis patients | 25 |
collected using | 25 |
significant change | 25 |
small dogs | 25 |
maternal plasma | 25 |
care system | 25 |
new automated | 25 |
urea nitrogen | 25 |
patients whose | 25 |
falciparum malaria | 25 |
cell membranes | 25 |
potassium level | 25 |
i min | 25 |
molecular diagnostics | 25 |
average number | 25 |
second group | 25 |
respiratory acidosis | 25 |
blood shortages | 25 |
left ventricle | 25 |
significant effect | 25 |
kupffer cell | 25 |
three blood | 25 |
based blood | 25 |
maintain hydration | 25 |
developed countries | 25 |
based transfusion | 25 |
surgical treatment | 25 |
undergoing elective | 25 |
apheresis donors | 25 |
organ injury | 25 |
signs associated | 25 |
ear canal | 25 |
lactic acidosis | 25 |
aortic aneurysm | 25 |
vascular tone | 25 |
turnaround time | 25 |
test result | 25 |
randomized clinical | 25 |
effective method | 25 |
experimental studies | 25 |
storage duration | 25 |
abo group | 25 |
prospectively studied | 25 |
multiplex pcr | 25 |
rh typing | 25 |
early phase | 24 |
intracranial pressure | 24 |
positive reactions | 24 |
using pcr | 24 |
national haemovigilance | 24 |
frequently used | 24 |
cell anemia | 24 |
anhepatic stage | 24 |
local blood | 24 |
platelet antibodies | 24 |
cell yield | 24 |
inflammatory cells | 24 |
small bowel | 24 |
prospective studies | 24 |
patients using | 24 |
stored rbcs | 24 |
molecular mechanisms | 24 |
ultrio assay | 24 |
factor xii | 24 |
study suggests | 24 |
volunteer donors | 24 |
storage conditions | 24 |
core antigen | 24 |
organ systems | 24 |
cardiovascular surgery | 24 |
deficiency anemia | 24 |
oxygen carrier | 24 |
pulmonary complications | 24 |
major challenge | 24 |
sudden death | 24 |
thalassemic patients | 24 |
infection may | 24 |
special attention | 24 |
negative patients | 24 |
studies show | 24 |
therapeutic approach | 24 |
first group | 24 |
tissue oxygen | 24 |
pulmonary arteries | 24 |
give blood | 24 |
donor return | 24 |
one day | 24 |
american association | 24 |
several weeks | 24 |
may influence | 24 |
also increased | 24 |
less likely | 24 |
molecular basis | 24 |
right hand | 24 |
independent risk | 24 |
blood utilization | 24 |
via blood | 24 |
process control | 24 |
deleterious effects | 24 |
hb content | 24 |
advisory committee | 24 |
frequency antigens | 24 |
culture results | 24 |
inhalation injury | 24 |
many different | 24 |
dried blood | 24 |
peritoneal dialysis | 24 |
transfusion hepatitis | 24 |
binding protein | 24 |
true positive | 24 |
short time | 24 |
glucose level | 24 |
donor deferrals | 24 |
dna extraction | 24 |
blood conservation | 24 |
positive test | 24 |
generally accepted | 24 |
bleeding tendency | 24 |
transfusion history | 24 |
specific gravity | 24 |
pall ebds | 24 |
success rate | 24 |
may allow | 24 |
transfusion centers | 24 |
dead space | 24 |
photochemical treatment | 24 |
risk management | 24 |
cde cde | 24 |
barrier function | 24 |
malaria infection | 24 |
complications associated | 24 |
wistar rats | 24 |
selected patients | 24 |
five days | 24 |
side effect | 24 |
oral iron | 24 |
fluid volume | 24 |
flow cytometer | 24 |
laboratory parameters | 24 |
organ transplant | 24 |
surgical icu | 24 |
may benefit | 24 |
new method | 24 |
immune complexes | 23 |
cellular blood | 23 |
crp levels | 23 |
anemic patients | 23 |
higher doses | 23 |
reactive samples | 23 |
dna sequencing | 23 |
anterior chamber | 23 |
clinical condition | 23 |
intestinal wall | 23 |
potentially infectious | 23 |
severe bleeding | 23 |
molecular typing | 23 |
inflammatory responses | 23 |
first transfusion | 23 |
linked immunosorbent | 23 |
avian influenza | 23 |
lymphoid lymphatic | 23 |
standard deviations | 23 |
two dogs | 23 |
biliary tract | 23 |
aseptically scrub | 23 |
cell leukemia | 23 |
rbc products | 23 |
ebola virus | 23 |
low birth | 23 |
male patients | 23 |
ang ii | 23 |
levels increased | 23 |
main cause | 23 |
lymphoid organs | 23 |
study evaluated | 23 |
main reason | 23 |
evidence based | 23 |
iron status | 23 |
respiratory function | 23 |
donor safety | 23 |
erythrocyte antibodies | 23 |
ultraviolet light | 23 |
system failure | 23 |
slightly lower | 23 |
intracranial hemorrhage | 23 |
inferior vena | 23 |
fulminant hepatic | 23 |
transfusion laboratory | 23 |
ventilator settings | 23 |
survival rates | 23 |
airway disease | 23 |
control animals | 23 |
rhd beadchip | 23 |
mean volume | 23 |
made using | 23 |
large amount | 23 |
inventory levels | 23 |
blood systems | 23 |
possible risk | 23 |
nasal discharge | 23 |
st day | 23 |
fi brinogen | 23 |
elective surgery | 23 |
detection system | 23 |
low doses | 23 |
inhaled nitric | 23 |
organ perfusion | 23 |
oxygenation index | 23 |
positive reaction | 23 |
false positives | 23 |
respiratory alkalosis | 23 |
insulin therapy | 23 |
donor pool | 23 |
room air | 23 |
tubular necrosis | 23 |
energy expenditure | 23 |
serological tests | 23 |
using standard | 23 |
rh antigens | 23 |
haemoglobin level | 23 |
prospective randomized | 23 |
antigen negative | 23 |
factor levels | 23 |
increasing number | 23 |
lps stimulation | 23 |
pd deficiency | 23 |
platelet factor | 23 |
host response | 23 |
working party | 23 |
prothrombin complex | 23 |
significantly less | 23 |
wedge pressure | 23 |
last months | 23 |
white matter | 23 |
pancreatic cancer | 23 |
hong kong | 23 |
months post | 23 |
abdominal sepsis | 23 |
voluntary non | 23 |
energy metabolism | 23 |
using commercial | 23 |
significant proportion | 23 |
roc curve | 23 |
adverse effect | 23 |
febrile non | 23 |
made based | 23 |
biochemical parameters | 23 |
hna antibodies | 23 |
hospital length | 23 |
chest syndrome | 23 |
sepsis patients | 23 |
middle east | 23 |
rectal temperature | 23 |
solvent detergent | 23 |
virus transmission | 23 |
graft versus | 23 |
cell adhesion | 23 |
new zealand | 23 |
antibody titer | 23 |
transfusion requirement | 23 |
fluid balance | 23 |
higher concentrations | 23 |
acquired immunodeficiency | 23 |
standard serological | 23 |
pg kg | 23 |
group showed | 23 |
may reveal | 23 |
taken together | 23 |
coagulation disorders | 23 |
study conducted | 23 |
polyclonal anti | 23 |
severe complications | 23 |
peritoneal macrophages | 23 |
fibrin degradation | 23 |
within hour | 22 |
definitive diagnosis | 22 |
ischemia reperfusion | 22 |
antibody positive | 22 |
mean blood | 22 |
clinical disease | 22 |
preterm infants | 22 |
refill time | 22 |
plasmodium parasites | 22 |
ventricular dysrhythmias | 22 |
different groups | 22 |
may take | 22 |
risks associated | 22 |
fl uid | 22 |
dysfunction syndrome | 22 |
female patient | 22 |
oncotic pressure | 22 |
high specificity | 22 |
circulatory failure | 22 |
clinical pathology | 22 |
intestinal mucosal | 22 |
west africa | 22 |
pericardial effusion | 22 |
limited number | 22 |
autoimmune haemolytic | 22 |
remains unknown | 22 |
lymphoid follicles | 22 |
old woman | 22 |
four years | 22 |
activator inhibitor | 22 |
haemolytic transfusion | 22 |
highly significant | 22 |
mayo clinic | 22 |
interquartile range | 22 |
hepatic blood | 22 |
blood centres | 22 |
dna analysis | 22 |
whitney test | 22 |
results may | 22 |
preoperative autologous | 22 |
lps challenge | 22 |
support ventilation | 22 |
candida albicans | 22 |
germinal centers | 22 |
platelet production | 22 |
dendritic cells | 22 |
using blood | 22 |
pathogen reduced | 22 |
among others | 22 |
medical therapy | 22 |
clinical diagnosis | 22 |
treated platelets | 22 |
analgesic drugs | 22 |
capillary refill | 22 |
free fetal | 22 |
newly developed | 22 |
antibiotic treatment | 22 |
interstitial pneumonia | 22 |
organ transplantation | 22 |
single dose | 22 |
three cases | 22 |
rapid detection | 22 |
twice daily | 22 |
hepatic function | 22 |
also showed | 22 |
task force | 22 |
also present | 22 |
rna positive | 22 |
time intervals | 22 |
antibodies directed | 22 |
patients included | 22 |
varying degrees | 22 |
may contain | 22 |
brain stem | 22 |
phase proteins | 22 |
million donations | 22 |
hours following | 22 |
patient characteristics | 22 |
one single | 22 |
two months | 22 |
will increase | 22 |
base excess | 22 |
first described | 22 |
medical university | 22 |
study using | 22 |
granulation tissue | 22 |
hepatic arterial | 22 |
one donor | 22 |
may represent | 22 |
synovial fluid | 22 |
therapeutic effect | 22 |
may decrease | 22 |
treated group | 22 |
antiinflammatory drugs | 22 |
poorly understood | 22 |
platelets may | 22 |
reduce blood | 22 |
susceptibility testing | 22 |
old man | 22 |
reactive results | 22 |
healthy adult | 22 |
may therefore | 22 |
remained stable | 22 |
leukocyte antibodies | 22 |
total parenteral | 22 |
male patient | 22 |
serum il | 22 |
infected individuals | 22 |
patients presented | 22 |
policy makers | 22 |
surface expression | 22 |
binding sites | 22 |
oxygen supplementation | 22 |
crystalloid fluid | 22 |
aortic valve | 22 |
found positive | 22 |
total bilirubin | 22 |
may suggest | 22 |
every day | 22 |
may induce | 22 |
gastric emptying | 22 |
rhd weak | 22 |
pulmonary fibrosis | 22 |
several factors | 22 |
rank test | 22 |
next step | 22 |
vascular endothelial | 22 |
intercostal space | 22 |
mean airway | 22 |
serum tt | 22 |
coma scale | 22 |
respiratory support | 22 |
university medical | 22 |
multiple transfusions | 22 |
time spent | 22 |
blood ordering | 22 |
national guidelines | 22 |
important cause | 22 |
patient outcome | 22 |
samples showed | 22 |
point mutation | 21 |
vitro study | 21 |
clinically normal | 21 |
receive either | 21 |
clinical impact | 21 |
relative risk | 21 |
health services | 21 |
may still | 21 |
evaluate whether | 21 |
solid organ | 21 |
genotyping results | 21 |
apheresis procedure | 21 |
well documented | 21 |
igg antibodies | 21 |
negative samples | 21 |
thromboembolic events | 21 |
hours prior | 21 |
glucose concentration | 21 |
prophylactic platelet | 21 |
early treatment | 21 |
first months | 21 |
insulin resistance | 21 |
intrauterine transfusions | 21 |
per group | 21 |
upper limit | 21 |
mrna expression | 21 |
trend towards | 21 |
vista tm | 21 |
mean weight | 21 |
uremic syndrome | 21 |
plt transfusions | 21 |
magnetic cards | 21 |
anticoagulated blood | 21 |
toxicity include | 21 |
autosomal recessive | 21 |
hev rna | 21 |
abo histo | 21 |
negative predictive | 21 |
sectional study | 21 |
cell antibody | 21 |
pcr assay | 21 |
every patient | 21 |
transfused blood | 21 |
randomly selected | 21 |
closed system | 21 |
chronic pain | 21 |
traumatic injury | 21 |
aortic arch | 21 |
muscle weakness | 21 |
clostridium difficile | 21 |
many factors | 21 |
health problem | 21 |
oxygen tension | 21 |
bile acids | 21 |
well understood | 21 |
emergency blood | 21 |
mean sem | 21 |
studies using | 21 |
total rna | 21 |
last decade | 21 |
external quality | 21 |
liver damage | 21 |
muscle tremors | 21 |
donors may | 21 |
significant impact | 21 |
clinical study | 21 |
animals may | 21 |
ae sd | 21 |
patients compared | 21 |
cell damage | 21 |
activated factor | 21 |
hla typing | 21 |
old individuals | 21 |
breathing pattern | 21 |
day post | 21 |
syndrome coronavirus | 21 |
testing methods | 21 |
patient data | 21 |
follow procedures | 21 |
cell concentrate | 21 |
randomized study | 21 |
least hours | 21 |
south america | 21 |
theraflex mb | 21 |
rhd gamma | 21 |
health sciences | 21 |
detection methods | 21 |
care hospital | 21 |
several hours | 21 |
calcium gluconate | 21 |
severely injured | 21 |
groups according | 21 |
repeated blood | 21 |
platelet loss | 21 |
small sample | 21 |
initial dose | 21 |
ductus arteriosus | 21 |
dat positive | 21 |
repeat testing | 21 |
vascular dilatation | 21 |
normal subjects | 21 |
prospective cohort | 21 |
low ferritin | 21 |
consensus conference | 21 |
high affinity | 21 |
coagulation cascade | 21 |
solid tumors | 21 |
negative effects | 21 |
major blood | 21 |
blood processing | 21 |
transfusion strategies | 21 |
hydrogen peroxide | 21 |
serum cobalamin | 21 |
effective use | 21 |
cell antigen | 21 |
cns excitation | 21 |
platelet recovery | 21 |
anaplasma phagocytophilum | 21 |
lactate production | 21 |
haemorrhagic shock | 21 |
plasma components | 21 |
free hemoglobin | 21 |
normal ranges | 21 |
chinese blood | 21 |
oxygen transport | 21 |
remains unclear | 21 |
transfused units | 21 |
oxide synthase | 21 |
breast milk | 21 |
volunteer blood | 21 |
sample volume | 21 |
primed donor | 21 |
third day | 21 |
tissue hypoxia | 21 |
cell culture | 21 |
overall survival | 21 |
effective way | 21 |
facs analysis | 21 |
molecular diagnostic | 21 |
predonation hb | 21 |
intraocular pressure | 21 |
normal plasma | 21 |
blood gathering | 21 |
severe fever | 21 |
research institute | 21 |
patient populations | 21 |
brain damage | 21 |
ventricular fibrillation | 21 |
panel cells | 21 |
took place | 21 |
high rates | 20 |
shed blood | 20 |
removal rates | 20 |
high cost | 20 |
left atrium | 20 |
also contribute | 20 |
marrow transplant | 20 |
closely related | 20 |
blood demand | 20 |
medical school | 20 |
several times | 20 |
family history | 20 |
hemolytic uremic | 20 |
tissue samples | 20 |
statistical significant | 20 |
positive impact | 20 |
primary endpoint | 20 |
clinical cases | 20 |
chronic bronchitis | 20 |
control resuscitation | 20 |
literature review | 20 |
transfusion support | 20 |
donor health | 20 |
intestinal epithelial | 20 |
data showed | 20 |
artificial oxygen | 20 |
plasma using | 20 |
right lateral | 20 |
patients transfused | 20 |
immunodeficiency syndrome | 20 |
chronic obstructive | 20 |
blood meal | 20 |
published data | 20 |
will lead | 20 |
antibody specificity | 20 |
liver cells | 20 |
vascular surgery | 20 |
rna detection | 20 |
dna testing | 20 |
blood testing | 20 |
lung water | 20 |
blood inventory | 20 |
total plasma | 20 |
phase i | 20 |
additional studies | 20 |
random donor | 20 |
typing results | 20 |
negative controls | 20 |
one group | 20 |
immunocompromised patients | 20 |
platelet dysfunction | 20 |
operative day | 20 |
cut surface | 20 |
haemoglobin levels | 20 |
flow chart | 20 |
nonregenerative anemia | 20 |
anion gap | 20 |
red wines | 20 |
laboratory test | 20 |
pulmonary valve | 20 |
south african | 20 |
haemoglobin concentration | 20 |
laboratory rabbits | 20 |
low serum | 20 |
ae ml | 20 |
labile blood | 20 |
activated clotting | 20 |
peritoneal lavage | 20 |
vast majority | 20 |
final product | 20 |
diagnostic value | 20 |
irregular antibodies | 20 |
common finding | 20 |
filter paper | 20 |
calcium levels | 20 |
hcv antibody | 20 |
nucleotide polymorphisms | 20 |